Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Wells Fargo analyst Stephen Baxter maintained Cardinal Health with an Equal-Weight and raised the price target from $135 to ...

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Jefferies Financial Group upgraded shares of Cardinal Health (NYSE:CAH – Free Report) from a hold rating to a buy rating in a report released on Wednesday morning, Marketbeat reports. The brokerage ...

Shares of Cardinal Health Inc. CAH advanced 1.82% to $127.45 Wednesday, on what proved to be an all-around great trading ...

Robust demand across its pharmaceutical and specialty solutions segment was the impetus behind Cardinal Health raising its fiscal 2025 enterprise guidance, said Jason Hollar, CEO of Cardinal ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Twist Bioscience (TWST – Research Report), ...

Dublin, Ohio-based Cardinal Health, Inc. (CAH) manufactures and distributes pharmaceuticals, medical & laboratory products, ...

It was the Cardinal’s birthday. The thing is, what do you tell a Cardinal? I know it’s not mazel tov. And what do you give a Cardinal? Forget wardrobe, jeans or a puffer jacket. Can’t go ...

Headquartered in Columbus, Ohio, Cardinal Health is a global, integrated healthcare services and products company that generated $205 billion in revenue in its fiscal year 2023. The company plays ...